Vitality Watch

Dossier pubmed preclinical 03-apr-2026
Animal model, organoid, or cell-culture result — not yet human

A 3-N nose-to-brain urolithin a nanomotor targeting microglial mitophagy in neuroinflammation.

Key claim: A biomimetic self-propelled urolithin A nanomotor delivered intranasally enhanced microglial mitophagy and reduced neuroinflammation, oxidative stress, and cognitive impairment in LPS-induced cell and animal models.

Abstract

Cognitive impairment is the primary manifestation of neuroinflammation-related central nervous system diseases. Intranasal administration is an effective method, bypassing the blood-brain barrier and delivering drugs to the brain. Herein, we designed a biomimetic self-propelled nanomotor with an inflammation-targeting capacity. This nanomotor comprised a hollow mesoporous manganese dioxide (HMnO) core and a polydopamine (PDA) shell. HMnOeffectively catalyzed the conversion of endogenous HOinto HO and O, enabling the movement of the nanomotor into a wider area to reduce neuroinflammation. The nanomotor was loaded with the natural compound urolithin A (UA), which significantly improved the bioavailability of the compound and enhanced mitophagy. Furthermore, PDA modification imparted the nanomotor with strong adhesive properties, enabling them to anchor effectively to the olfactory nerve and enhancing delivery to the brain. In vitro, PDA@HMnO@UA alleviated mitochondrial dysfunction, oxidative stress, and inflammation levels by enhancing mitophagy in lipopolysaccharide (LPS)-induced BV2 cells. Following intranasal administration, PDA@HMnO@UA exerted neuroprotective effects by alleviating microglial activation, neuroinflammation, and neuronal loss, ultimately rescuing the neurocognitive function in the LPS-induced neuroinflammation model. In summary, this study presents an ideal nanomotor platform based on the 3-N strategy, which means “Nanomotor loaded with a Natural product to traverse a Natural anatomical pathway,” that can alleviate cognitive impairments caused by neuroinflammation, offering a promising delivery approach for treating neuroinflammatory diseases.

Why this matters

Urolithin A’s CNS translation has been limited by poor brain exposure, and this nanomotor is a preclinical attempt to force the mitophagy-restoration mechanism past the blood–brain barrier via intranasal delivery to microglia. It sits inside an already-crowded urolithin A → PINK1/Parkin → neuroinflammation preclinical narrative, so the contribution is a delivery/formulation advance rather than new mechanistic ground. Human cognitive or neuroinflammation endpoints for any UA formulation remain untested.

Source

Link

Briefing card

A 3-N nose-to-brain urolithin a nanomotor targeting microglial mitophagy in neuroinflammation.
Stage: preclinical · pubmed · 03-apr-2026

If you're tracking urolithin A for brain aging, this remains a mouse-stage delivery experiment and does not change what oral urolithin A has been shown to do in people.

A biomimetic self-propelled urolithin A nanomotor delivered intranasally enhanced microglial mitophagy and reduced neuroinflammation, oxidative stress, and cognitive impairment in LPS-induced cell and animal models.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1016/j.biomaterials.2026.124162

build build 880 · 2bcef25 · 2026-11-18